Beijing Cheng Da Tianhe Biotechnology Co., Ltd., a wholly-owned subsidiary of Liaoning Cheng Da Biotechnology Co., Ltd. (CDBIO) is a modern state-controlled biotechnology company dedicated to the research and development (R&D) of innovative vaccines within the realm of biopharmaceuticals, whose business scope encompasses the technology development, technology services, technology consultations, and technology transfer of innovative vaccines in the biopharmaceutical field.

CDBIO (Tianhe) has established two R&D bases in the Beijing Economic and Technological Development Area with the aggregate construction area of the laboratories surpasses 5,000 square meters. Upholding innovation as the core philosophy, CDBIO (Tianhe) closely tracks the cutting-edge trends in domestic and international biomedical R&D, and has successfully erected a domestically preeminent innovative vaccine-related technology platforms which encompass multiple R&D platforms including technology platforms of the high-density cell fermentation, the bacterial capsular polysaccharide purification and the polysaccharide-protein conjugation. The company is fully capable of implementing the entire process, ranging from the vaccine project approval of R&D to the pilot-scale production. CDBIO (Tianhe) has constructed analytical platform for the biochemistry and biology equipped with state-of-the- art domestic and international instruments. These platforms enable the rapid analysis and the identification of diverse sample types including vaccines, bacterial capsular polysaccharides, conjugates, recombinant proteins, and antibodies, etc. Furthermore, the CDBIO (Tianhe) is set to build high-standard clean laboratories and is in the process of preparing to establish expression platforms of Escherichia. Coli. (E. Coli.), yeast and a CHO cell. Once these construction projects are completed, CDBIO (Tianhe) will achieve comprehensive coverage of expression platforms spanning from prokaryotes to mammalian cells.

The team members have extensive experience accumulated over many years in the fields of R&D, production, and quality management of vaccine laying a solid and robust foundation for the orderly progression of the project. CDBIO (Tianhe)'s management have been continuously engaged in R&D, production, and quality assurance of vaccine-based biological products for a period exceeding 20 years with the highly profound professional proficiency and the exceedingly rich experience on R&D management, which offer a powerful promise for the establishment of the vaccine technology platform and the smooth advancement of projects.

At present, the projects approved by CDBIO (Tianhe) include the R&D of biological products such as multi-valent pneumococcal polysaccharide conjugate vaccine, quadri-valent meningococcal conjugate vaccine, recombinant protein vaccine, pediatric respiratory combined vaccine, multi-valent Serogroup B meningococcal OMV, rabies monoclonal antibody, and various antibodies. Thereinto, several projects have obtained clinical trial approvals and entered the clinical trial stage, and some cutting-edge vaccine projects have entered the R&D stage. It is believed that clinical trial approvals of mentioned cutting-edge vaccine can also be obtained within next 3 to 5 years, and they will be further transformed into industrialization to achieve the substantial profit growth points for the company.

The green and environmentally friendly design concept is adopted to all R&D projects with advanced technical means to improve the existing process technologies, especially for the employment of safe, environmentally friendly and harmfulless chemical reagents and raw materials to replace the harmful or corrosive organic solvents in traditional processes. The innovation of traditional technologies will promote the transformation from a pollution-generating company to an environmentally friendly one. The breakthrough of technical barriers will break the long-term monopoly of multi-national companies in Chinese high-end human vaccines and promote the progress of Chinese vaccine production technology. The company strengthens the protection of intellectual property rights through the application for a series of invention patents to enhance the independent development capability, and to provide the promise for the sustainable development of the company. Meanwhile, the company actively follows the development trend of major national infectious diseases to establish a rapid response mechanism for new explosive diseases that have a significant impact on public health, and strives to apply for and undertake national scientific and technological projects such as national major projects of the R&D for the new drug of the science and technology, and the infectious disease prevention and control, making contributions to the prevention of major infectious diseases.

Talent serves as the wellspring of impetus for innovative development and constitutes a critically significant intangible asset of a company. CDBIO (Tianhe) is characterized by a far-reaching strategic mindset regarding talent with a relatively consummating talent cultivation and incentive scheme to furnish comparatively comprehensive development prerequisites, integrating both software and hardware resources for talent. CDBIO (Tianhe) adheres to the coordinated approach of internal-external synergy steadfastly, constructs an open-minded and inclusive R&D center, and further intensifies collaboration with domestic and international universities and institutions heightening the level of the informatization construction and the internal scientific management, and attracting outstanding technical talents to seek employment here and welcoming relevant researchers to bring their research outcomes for transformation from both domestic and international arenas.